- Conditions
- Non Arteritic Anterior Ischemic Optic Neuropathy
- Interventions
- QPI-1007 Injection - 1.5 mg, QPI-1007 Injection - 3.0 mg, Sham Injection Procedure
- Drug · Other
- Lead sponsor
- Quark Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 732 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 44
- States / cities
- Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 35 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), Trauma, Multiple Sclerosis (MS)
- Interventions
- Transcorneal Electrical Stimulation, Sham
- Device
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Anterior Ischemic Optic Neuropathy
- Interventions
- Diagnostic procedures
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 11
- States / cities
- Vista, California • Atlantis, Florida • Fort Myers, Florida + 7 more
- Conditions
- Nonarteritic Anterior Ischemic Optic Neuropathy
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
- Interventions
- ER-100 epigenetic therapy
- Genetic
- Lead sponsor
- Life Biosciences Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 4
- States / cities
- Glendale, California • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Non Arteritic Ischemic Optic Neuropathy
- Interventions
- dalfampridine, Placebo
- Drug
- Lead sponsor
- Neuro-Ophthalmologic Associates, PC
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non-Arteritic Anterior Ischemic Optic Neuropathy
- Interventions
- Cenegermin, Vehicle
- Drug · Other
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Newport Beach, California • Aurora, Colorado + 13 more
- Conditions
- Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy
- Interventions
- QPI-1007 at various doses
- Drug
- Lead sponsor
- Quark Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 19 more